Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals (Nasdaq: CRVS) will host a conference call and webcast on May 8, 2023, at 4:30 PM ET to discuss a business update and report first quarter 2023 financial results. Investors can join the call by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (international) and using passcode 2096044. A live webcast will also be available through the investor relations section on the Corvus website.
Corvus Pharmaceuticals is focused on developing novel therapies for cancer. Its lead candidate, CPI-818, is in a Phase 1/1b trial aimed at T cell lymphomas, while two additional programs, CPI-444 and CPI-006, are also in various stages of clinical trials. The company continues to advance its innovative pipeline in the biopharma sector.
Corvus Pharmaceuticals (Nasdaq: CRVS) has announced promising preclinical data for its investigational drug CPI-818, an ITK inhibitor aimed at treating various cancers. The data, presented at the AACR Annual Meeting, indicates CPI-818 effectively inhibits tumor growth in models of colon, renal, and melanoma cancers, as well as T and B cell lymphomas. The mechanism of action involves enhancing T cell differentiation and reducing T cell exhaustion, potentially positioning CPI-818 for broad cancer immunotherapy applications. The company is currently enrolling patients in a Phase 1/1b trial focusing on T cell lymphoma and plans to meet with the FDA to discuss a Phase 3 trial. Corvus anticipates presenting updated clinical trial data in the second quarter of 2023.
Corvus Pharmaceuticals (Nasdaq: CRVS) recently presented interim data from its Phase 1/1b clinical trial of CPI-818 for T cell lymphoma at the Whistler Global Summit on Hematologic Malignancies. The data, revealed by Dr. John Reneau, indicates promising results with CPI-818 demonstrating monotherapy activity in relapsed patients. Key findings include one complete response lasting 24 months and an overall median progression-free survival (PFS) of 28.1 months for patients with an absolute lymphocyte count (ALC) above 900. Corvus aims to leverage this biomarker for patient enrollment in future trials.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
